DEAN'S MESSAGE |
Dr. Davis is the Arline H. and Curtis F. Garvin Research Professor at Case Western Reserve University, the Chief of the Pediatric Pulmonary Division at Rainbow Babies and Childrens' Hospital, and Professor of Pediatrics, Physiology & Biophysics, and Molecular Biology & Microbiology at Case Western Reserve University, and Senior Associate Dean for Research at the School of Medicine. She received the A. B. degree summa cum laude from Smith College, Northampton, MA, and the M.D. and Ph.D. degrees from Duke University. After completing an internship and residency in Medicine at Duke Hospital, she became a Clinical Associate in the Pediatric Metabolism Branch of NIDDK (then NIAMDD) where she received fellowship training in Pulmonary Medicine (via the NHLBI). In 1981, she moved to Case Western Reserve University where she rose through the ranks to her current position.
Dr. Davis directs the Willard A. Bernbaum Cystic Fibrosis Research Center at Case Western Reserve University, which is the site of a Core Center from NIDDK and a Research Development Center for the Cystic Fibrosis Foundation. Dr. Davis has published more than 120 original articles, mostly in the area of cystic fibrosis research, edited one book, contributed numerous book chapters, and served as Associate Editor for several journals.
She holds seven U.S. Patents, is a founding scientist of Copernicus Therapeutics, Inc, and serves on the Scientific Advisory Board of Arizeke, Inc, to which some of her patents are also licensed. She has served on the Advisory Council to NIDDK, on the Board of Scientific Counselors for NHLBI, and on advisory boards for the Burroughs Wellcome Fund and several academic cystic fibrosis centers. She is the recipient of the Rosenthal Prize for academic pediatrics, the Smith College Medal, and has been named regularly in Best Doctors in America and Top Doctors. She was inducted into the Cleveland Medical Hall of Fame.
Her major research interest is in cystic fibrosis, specifically the structure and function of the CFTR molecule, how the cystic fibrosis lung disease arises, and strategies for gene therapy of cystic fibrosis. The interest in the CF lung disease has broadened into a more general interest in lung inflammation, and the strategies she has developed for gene therapy of CF now seem applicable to a broader range of human disease as well.
Pamela B. Davis, M.D., Ph.D.
Interim Dean, School of Medicine
|
